GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Float Percentage Of Total Shares Outstanding

Arena Pharmaceuticals (FRA:RN3N) Float Percentage Of Total Shares Outstanding : 86.12% (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arena Pharmaceuticals's float shares is 53.10 Mil. Arena Pharmaceuticals's total shares outstanding is 61.66 Mil. Arena Pharmaceuticals's float percentage of total shares outstanding is 86.12%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arena Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arena Pharmaceuticals's Institutional Ownership is 54.37%.

Arena Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Arena Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=53.10/61.66
=86.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
AXSM VIE QURE AMRN KOD FATE NVAX DNLI ALKS FOLD OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Website
https://www.arenapharm.com
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines